InVivo Therapeutics announced the appointment of Mark D. Perrin as CEO, effective Jan. 6. Perrin, who will also assume a spot on the company’s Board of Directors, succeeds interim CEO Michael Astrue, who has served in that position since the resignation of Francis Reynolds for medical reasons in August.
Most recently serving as the president of biotech consulting firm Dennen Consulting, Perrin has held the positions of president and CEO at ConjuChem Biotechnologies, as well as EVP and chief commercial officer for Orphan Medical. His professional history also includes stints heading up US commercial operations at both Burroughs Wellcome and Lederle Laboratories.
“Mark is an excellent fit for InVivo,” said company chairman John McCarthy. “His extensive commercial background will be invaluable.”
McCarthy also noted that Perrin’s “solid experience raising money” will be important to the company as it continues to focus its resources on “high-value opportunities that maximize long-term value.”
McCarthy also praised Astrue’s accomplishments, noting that his initiatives “greatly improved management of the company.”
